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Abstract 
Purpose: Cognitive impairment and reduced quality of life is a common condition in patients with heart failure (HF). 
Percutaneous mitral valve repair using (PMVR) MitraClip (MC) has emerged as a promising interventional tool, reduc‑
ing all‑cause mortality and hospitalization as well as increasing cognitive functioning and quality of life. However, the 
benefit of HF patients with severely depressed cognitive functioning remains unknown.
Methods: We assessed cognitive functioning (figural memory—FGT, executive function—TOL, TMT B), psychosocial 
functioning (depression—PHQ‑9, quality of life—SF36), and clinical parameters (echocardiography, 6‑min walk test 
distance, and cardiac biomarkers) 1 day before (t0) and 6 weeks after (t1) MC intervention in HF patients (n = 40). 
First, paired sample t tests were conducted to uncover improvements in cognitive functioning post‑MC intervention. 
Second, the COGBAT Norm‑sample, a representative age‑matched healthy sample, was used to compare participants’ 
individual scores. Third, bivariate linear regressions were calculated for all key predictors of the detected improve‑
ments in cognitive functioning post‑MC intervention (t1–t0).
Results: Following the MC intervention, we found significant improvements in figural memory, executive func‑
tioning, and psychosocial functioning. Most of the patients with depressed executive functioning before the MC 
intervention showed post‑intervention test scores within the normal range (> 50th percentile; t0 22.5% vs. t1 60%) 
as compared to the normative COGBAT sample. Regression analyses revealed that lower baseline scores in planning 
ability before the MC intervention (t0) were associated with greater planning ability (TOL; B = − 0.78, 95% CI − 1.04 to 
− 0.53), figural memory (FGT; B = − 0.26, 95% CI − 0.44 to − 0.07), and cognitive flexibility (TMT B; B = − 0.36, 95% CI 
− 0.50 to − 0.23) improvement post‑MC intervention (t1–t0). Psychosocial functioning and age were not associated 
with these improvements.
Conclusions: Patients with depressed executive functioning showed the greatest benefit from the MC intervention 
regarding cognitive functioning. Age and psychological functioning seem less important for cognitive performance 
improvements post‑MC intervention. Hence, severely depressed cognitive functioning in patients is not a contraindi‑
cation for PMVR using MitraClip.
Keywords: Chronic heart failure, MitraClip intervention, Cognitive performance, Memory, Executive function, 
Depression, Quality of life
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Introduction
Systolic heart failure (HF) is a major cause of morbid-
ity and mortality worldwide [1, 2]. The disease is incur-
able and progressive and exhibits a 5-year mortality 
of ~ 50% [1, 2]. For more than 10 years, it has been known 
that the occurrence of severe mitral valve regurgitation 
(MR) aggravates cardiac remodeling, exacerbates clini-
cal symptoms and is an independent negative predictor 
of mortality in HF [3]. Moreover, HF patients commonly 
display burdensome psychosocial as well as cognitive 
symptoms, including impaired quality of life, concentra-
tion and alertness [2]. Recent studies, applying elaborate 
methodological paradigms to assess cognitive function-
ing, have confirmed an association between the severity 
of HF and cognitive impairment, particularly for the cog-
nitive domains of memory and executive functioning [4, 
5].
Percutaneous mitral valve (MV) repair (PMVR) using 
MitraClip is an established technique to treat severe 
mitral valve regurgitation (MR) in high-risk surgical 
patients after interdisciplinary discussion [1, 2, 5–11]. 
PMVR was recently shown to reduce all-cause mortal-
ity as well as hospitalization in patients with severe sys-
tolic HF [12]. Additionally, PMVR results in significant 
improvement of figural memory and planning ability 
as well as psychosocial functioning in HF patients [13]. 
Since there is a risk of withholding optimal medical treat-
ment to very sick HF patients and also a discussion about 
patients being “too sick” for PMVR, we aimed to assess 
the effects of PMVR using the MitraClip on psychologi-
cal and cognitive functioning as compared with the initial 
severity of psychological- and cognitive malfunctioning 
prior to PMVR.
Materials and methods
In a pre–post-interventional controlled trial, 40 patients 
with end-stage HF and severe mitral valve regurgitation 
were assessed pre- (1  day before; t0) and post-(6  weeks 
after; t1) MC intervention (MC; n = 40). We choose a 
6-week observation period, since there is evidence that 
patients recover from the minimal-invasive MC proce-
dure within 4 weeks [14] and to exclude unrelated effects 
which might occur within a longer period of time. The 
sample consisted of patients referred to the outpatient 
setting of the Heart Failure Section of the Department 
of Cardiology, Angiology and Pneumology of the Medi-
cal Hospital, University of Heidelberg between 2014 
and 2016 where all examinations including the MC pro-
cedure and cognitive testing were carried out. General 
inclusion criteria for the MC intervention were suffer-
ing from ischemic or dilated cardiomyopathy showing 
an ejection fraction of 35% or lower or being categorized 
as high-risk surgical HF patients due to reduced systolic 
function of below 45% combined with a Society of Tho-
racic Surgeons’ (STS) score of > 8%. The main exclusion 
criteria were morphological properties of the MV that 
would make MitraClip implantation unlikely or impos-
sible as published previously by Feldman et  al. [14]. All 
patients received stable optimized individual target 
heart failure medication at least for 3  months prior to 
MC intervention. We assessed questionnaires on socio-
demographic data (age, sex, school level), verbal- and 
education-related intelligence, eye vision, and handed-
ness [15], followed by the participants’ psychometric and 
neuropsychological assessment. Total testing time took 
approximately 150 min for both pre-assessment (t0) and 
re-assessment (t1). All participants were asked to avoid 
eating and drinking caffeinated beverages for 1 h before 
and smoking nicotine or consuming alcohol for 24 h prior 
to assessment. For cognitive testing, general inclusion 
criteria were right-handedness, normal or corrected-
to-normal vision, and native German language. Written 
informed consent was obtained from all participants as 
approved by the local ethics committee of the University 
of Heidelberg (No. S-243/2013).
The Cognitive Basic Assessment test set (COGBAT) 
from the Vienna test system [16] efficiently assesses the 
key neuropsychological dimensions of attention, mem-
ory, executive functions, and processing speed and has 
been validated across neurological and psychiatric popu-
lations [17, 18]. The tests are presented in a fixed order 
and take 60  min to complete. With regard to reliability, 
internal consistencies expressed as Cronbach’s α = 0.70–
0.92 can be determined as adequate to excellent. The 
assessed COGBAT cognitive dimensions are described in 
detail in our previous research [13]. Moreover, the COG-
BAT is cross-test normed enabling the comparison of 
individual scores to representative sample scores for the 
following age groups (in years): ‘16 to 30’ (N = 127), ‘31 to 
50’ (N = 151), and ‘51 to 80’ (N = 141).
We assessed the Patient Health Questionnaire (PHQ-
D; German version [19]), which is used to diagnose com-
mon mental health disorders. For the purpose of this 
study, the scores of the 9-item depression module are 
reported (PHQ-9; [20]). The PHQ-9 depression mod-
ule is designed to assess depressive symptoms, disorder 
severity, and symptom development [21]. It shows very 
good validity [22, 23] as well as sensitivity for change 
[24] measures and has yielded good results in testing 
depression in patients with chronic somatic diseases [25]. 
Mental and physical health-related quality of life was 
measured using the 36-item Short-Form General Health 
Survey (SF-36; German version [26]), which shows good 
reliability and internal consistency, and satisfying discri-
minant and convergent validity [26]. In this paper, the 
term psychosocial functioning refers to the degree of 
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depression (i.e., PHQ-9) as well as to the quality of life 
(i.e., SF-36).
To control for verbal and education-related intelli-
gence, participants completed the Multiple Selection 
Vocabulary Test (“Mehrfachwahl-Wortschatz-Intelli-
genztest”; MWT-B; [27]; see Table 1) at t0. The MWT-B 
comprises 37 rows of words, each of which consists 
of one German word which is colloquially, scientifi-
cally, or eruditely familiar and four nonsense words. 
Participants are required to recognize familiar words 
that exist in the German language. Scores are based on 
the number of correctly identified words (maximum of 
37). Investigations on re-test reliability have revealed 
high correlations [28].
A detailed overview of clinical, echocardiography, 
and invasive haemodynamic data as well as comorbidi-
ties is summarized in Table 1.
Table 1 Sample description for assessed MitraClip (MC group; N = 40)
MWT-B multiple selection vocabulary test, STS-score risk score of the Society of Thoracic Surgeons to predict operative mortality of adult cardiac surgery, NT-ProBNP 
N-terminal pro-brain natriuretic peptide, hsTnT high-sensitive Troponin T, ICMP ischemic cardiomyopathy, DCMP dilated cardiomyopathy, NYHA New York Heart 
Association, SD standard deviation, IQR interquartile range
Pre (t0) Post (t1)
COGBAT norm percentile (≥ 50 = healthy)
 Planning ability (median; IQR) 30 (11.25 to 42.50) 65 (35 to 80)
 Figural memory (median; IQR) 22.5 (0 to 50) 45 (16.25 to 75)
Patient characteristics and biomarkers
 Age (years; median) 73 –
 Sex (female) 19/40 (47.5%) –
 MWT‑B intelligence quotient (IQ) 110.83 ± 16.3 –
 STS‑score (%) 5.16 (5.24) –
 Psychopharmacological medication (n) 6 (15%) –
 Ejection fraction (%) 35 ± 15 35 ± 16
 6 min walk distance test (m) 366 ± 7 415 ± 115
 NT‑ProBNP (ng/L) (median) 3880 3627
 hsTnT (pg/mL) 36 ± 33 46 ± 80
Pathogenesis and comorbidity
 ICMP (%) 21/40 (52.5%) –
 DCMP (%) 19/40 (47.5%) –
 Implantable cardioverter defibrillator (%) 15/40 (37.5%) –
 Prior cardiothoracic surgery (%) 9/40 (22.5%) –
 Atrial fibrillation (%) 20/40 (50%) –
 Prior stroke (%) 4/40 (10%) –
 Increased retention values (> 1.3 mg/dL) (%) 11/40 (27.5%) –
 Severe sleep apnea syndrome (%) 4/40 (10%) –
 Diabetes mellitus (%) 6/40 (15%) –
 Pulmonary disease 8/40 (20%) –
 Cancer (%) 1/40 (2.5%) –
Functional Mitral valve regurgitation (FMR)
 FMR ≤ I° 0 14/40 (35%)
 FMR ≤ II° 0 23/40 (57.5%)
 FMR > II°–< III° 4/40 (10%) 3/40 (7.5%)
 FMR III° 11/40 (27.5%) 0
 FMR IV° 23/40 (57.5%) 0
NYHA functional classification
 NYHA I 0 1/40 (2.5%)
 NYHA II 3/40 (7.5%) 24/40 (60%)
 NYHA III 32/40 (80%) 15/40 (37.5%)
 NYHA IV 5/40 (12.5%) 0
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MC percutaneous edge-to-edge mitral valve repair 
procedure was performed under general anesthesia and 
under transesophageal echocardiographic guidance. 
Quantification of mitral regurgitation was carried out 
using transthoracic echocardiography, transesophageal 
echocardiography, left ventricular angiogram and inva-
sive measurements of pulmonary artery pressure and left 
atrial pressure as described previously [29]. After atrial 
transseptal puncture, mitral leaflets were approximated 
using the 24-French  MitraClip® device (Abbott Vas-
cular, Santa Clara, CA, USA). In the case of insufficient 
mitral regurgitation reduction with a single device, the 
device may either be removed or a second device placed 
[14, 29]. Hemostasis was achieved using the  ProGlide® 
device (Abbott Vascular, Santa Clara, CA, USA) as previ-
ously described by Geis et al. [30]. After the procedure, 
patients were transferred to the intensive care unit for at 
least 24 h.
Data were analyzed using SPSS (Version 25; SPSS Inc., 
Chicago, IL, USA). First, dependent t tests (t0 vs. t1) were 
conducted to reveal improvements of cognitive perfor-
mance in the MC group. A p value < 0.05 (two tailed) 
was considered statistically significant. Second, to deter-
mine predictors of the detected cognitive performance 
improvements, bivariate linear regressions were calcu-
lated (MC group; N = 40) with cognitive performance 
improvements (ΔT: t1–t0) as dependent variable and all 
key variables pre-intervention (t0) as independent vari-
ables. To minimize Type I errors, a Bonferroni familywise 
α error correction was applied on one-tailed p values 
(6-test family; corrected threshold p ≤ 0.008). Further-
more, repeated measures MANOVAs were conducted 
to explore possible group differences for patients with 
ischemic vs. dilated cardiomyopathy (ICMP vs. DCMP) 
of figural memory, planning ability, and cognitive flexibil-
ity with the within-subject factor ‘Time’ (t0 vs. t1).
Results
Participant baseline data
Table 1 shows participants’ baseline data. The MC patient 
group ranged from 31 to 86 years (M = 69.78, SD = 11.3), 
and 47.5% were female. With regard to the underlying 
pathogenesis of the existing HF, 52.5% of our patients 
(n = 21) show HF due to ischemic cardiomyopathy 
(ICMP) and 47.5% of our patients (n = 19) suffered from 
dilated cardiomyopathy (DCMP). At the time of assess-
ment, six of the 40 HF patients received psychopharma-
cological or opioid medication (antidepressants n = 3, 
benzodiazepines n = 2; opioid analgesics n = 1).
Comparison of cognitive functioning before and after 
the MitraClip intervention
As depicted in Table 2, dependent t tests revealed a sig-
nificant improvement of the MC group (N = 40) for 
figural memory (learning sum: t(39) = − 7.29, p < 0.001, 
d = 1.15), executive functions based on planning ability 
(t(39) = − 4.83, p < 0.001, d = 0.76) as well as cognitive 
flexibility (TMT B: t(39) = 3.82, p < 0.001, d = 0.60) from 
Table 2 Differences for  psychosocial, neuropsychological, and  clinical assessment pre  (t0) and  after  6  weeks (t1) post-
MitraClip intervention
PHQ-9 Patient Health Questionnaire, SF-36 Short-Form Health Survey, FGT figural memory test, TOL, Tower of London–Freiburg Version, TMT-L trail making test–
Langensteinbach version, LVEF left ventricular ejection fraction, 6-MWT 6-minute walk test, FMR functional mitral valve regurgitation, NT-ProBNP N-terminal pro-brain 
natriuretic peptide; Values are presented means, standard deviations, t value and p value. aPsychosocial assessment for N = 32
MC group (N = 40) Mean (SD) t p
t0 t1
Psychosocial  functioninga
 Depression‑score (PHQ‑9; 0–27) 6.44 (4.45) 3.78 (3.15) 4.57 < .001
 Psychological well‑being (SF‑36; 0–100) 68.75 (22.50) 77.88 (15.57) − 2.83 0.008
 Physical well‑being (SF‑36; 0–100) 43.66 (25.02) 59.84 (26.79) − 3.81 0.001
Cognitive functioning
 Figural memory learning sum (FGT; 0–45) 18.23 (8.98) 24.55 (8.34) − 7.29 < .001
 Planning ability (TOL; 0–24) 11.75 (4.14) 15.25 (3.36) − 4.83 < .001
 Cognitive flexibility (TMT: Part B) [s] 120.15 (63.54) 99.35 (47.83) 3.82 < .001
Clinical parameters
 LVEF 34.60 (14.95) 34.57 (15.64) 0.03 n.s.
 6‑MWT [s] 365.69 (6.64) 414.52 (115.40) − 3.57 0.001
 FMR 2.83 (0.64) 1.35 (0.48) 12.43 < .001
 NYHA 3.05 (0.54) 2.34 (.49) 8.14 < .001
 NT‑ProBNP 10,161.9 (20,141.1) 8159.5 (16,704.3) 2.28 0.029
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t0 to t1. To compare test results of the improved cog-
nitive functioning in the MC group to a sample of age-
matched healthy controls, the individual’s results were 
compared to the representative COGBAT sample includ-
ing healthy persons over all age groups (see Table 3 and 
Fig.  1). For ‘planning ability’, 78% (t0) versus 41.5% (t1), 
and for ‘figural memory’, 73.2% (t0) versus 58.5% (t1) 
obtained test scores below the 45th percentile compared 
to the COGBAT normative sample; this means that cog-
nitive performance was below the normal range before 
the MC intervention and that particularly planning abil-
ity improved showing test scores within the normal range 
post-MC intervention (median = 65).
Predictors of change in cognitive functioning due 
to the MitraClip intervention
Table  4 depicts bivariate linear regressions of baseline 
scores (t0) in (i) cognitive functioning (i.e., planning 
ability, figural learning, cognitive flexibility), and (ii) 
psychosocial functioning (i.e., PHQ-9, SF-36 psychologi-
cal well-being, SF-36 physical well-being) and age with 
cognitive performance improvements (t1–t0) due to the 
MC intervention. While psychosocial functioning and 
age were not associated with improvements in cognitive 
functioning, impaired planning ability, figural memory as 
well as cognitive flexibility at t0 were associated with bet-
ter cognitive functioning. Cognitive performance was not 
controlled for depression, as no correlations were found 
for pre–post-changes in PHQ-9 scores and pre–post-
changes in memory and executive function (all p > 0.05).
Comparison of psychological assessment before and after 
the MitraClip intervention
Table  3 depicts MC patients’ results of psychological 
assessment. Out of N = 40 MC patients, only N = 32 at 
t0 and N = 37 at t1 completed psychological assessment. 
Dependent t-tests (t0 vs. t1) were conducted, show-
ing significantly improved depression scores (PHQ-9: 
Table 3 Individual’s results in  pre–post-MitraClip planning ability as  well as  figural memory (MC group; N = 40) 
compared to the normative COGBAT sample
Percentile (t0) Percentile (t1)
≤ 20 ≤ 35 ≤ 50 > 50 ≤ 20 ≤ 35 ≤ 50 > 50
Planning ability, n (%) 17 (42.5) 30 (75.0) 31 (77.5) 9 (22.5) 6 (15.0) 12 (30.0) 16 (40.0) 24 (60.0)
Figural memory, n (%) 20 (50.0) 29 (72.5) 31 (77.5) 9 (22.5) 11 (27.5) 19 (47.5) 23 (57.5) 17 (42.5)
Fig. 1 Individual’s results in pre–post‑MitraClip planning ability as well as figural memory (MC group; n = 40) compared to the normative COGBAT 
sample, while test scores ≥ 50 indicate normal/ healthy cognitive functioning and test scores < 50 indicate impaired cognitive functioning in the 
respective domain. For planning ability, median test score values are shifting in the healthy area at t1 (post‑MC)
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t(31) = 4.57, p < 0.001, d = 0.81) as well as quality of life 
(SF36 psychological well-being: t(31) = − 2.83, p = 0.01, 
d = 0.5; SF36 physical well-being: t(31) = − 3.81, p < 0.001, 
d = 0.68) scores post-MC.
Cognitive performance before and after MitraClip 
intervention: ICMP vs. DCMP
Repeated MANOVAs were separately conducted for var-
ious cognitive domains with the between-subject factor 
‘Group’ (ICMP; n = 21 vs. DCMP; n = 19) and the within-
subject factor ‘Time’ (t0 vs. t1). There were no significant 
effects.
Discussion
The present study examined cognitive functioning in 
HF patients pre- and post-MC intervention. In line with 
our previous results [13], figural memory and executive 
functioning were significantly increased due to percuta-
neous mitral valve repair (PMVR) using MitraClip in HF 
patients.
Our results showed that HF patients show additional 
improvement in cognitive flexibility, reflected by the 
improved TMT B test scores 6 weeks after PMVR. Most 
importantly, the evaluation of cognitive functioning pre-
dictors revealed that poorer baseline figural memory 
and executive functioning correlated significantly with 
greater cognitive performance improvements, in the 
respective domains following the MC intervention irre-
spective of medical and psychological covariates.
The pathophysiology of impaired cognitive function-
ing seems to be diverse in elderly HF patients as reflected 
by their regular decline in decreased cognitive function-
ing ‘per se’ [31, 32] due to age-related changes in the 
brain [33–35]. Reduced cognitive reserve in the elderly 
is linked to a general higher risk of cognitive impairment 
[36]. HF is an additional risk factor for various disorders 
like dementia [37] or multiple cerebral emboli [38, 39]. 
In addition, post-operative cognitive dysfunction affects 
up to 54% of patients shortly after cardiac surgery [40]. 
Therefore, one could assume that elderly HF patients 
with poorer cognitive ability may fail to benefit from the 
MC intervention at a cognitive level and are particularly 
vulnerable to cognitive impairment after the interven-
tion [41]. However, in our sample age did not correlate 
with baseline scores and cognitive outcome post-MC 
intervention. In contrast, our results suggest that the age 
of HF patients plays a minor role, yet HF patients with 
poorer baseline cognitive functioning benefit the most 
with regard to their cognitive performance post-MC 
intervention.
One study using magnetic resonance imaging in 13 
high-risk patients undergoing percutaneous mitral valve 
reconstruction reported that the MitraClip procedure 
resulted in newly acquired cerebral lesions in 9 out of 13 
patients [42]. Similarly, others reported peri-interven-
tional thrombus formation and stroke [43–45]. However, 
in large registries the incidence of clinical relevant stroke 
within 30  days after MC is low and varies between 0.7 
and 2.6% [46–49]. Furthermore, we recently published a 
very low rate (0.2%; 1/470 patients) of 30-days peri-inter-
ventional stroke in patients treated in our hospital due 
to temporary oral anticoagulation for 30 days using cou-
madin [50]. Therefore, we might speculate that avoiding 
peri-interventional stroke due to temporary oral antico-
agulation using Coumadin for 30 days might support our 
findings of improved cognitive function.
The perfusion hypothesis states that insufficient 
blood circulation underlies cognitive deficits in 
patients with chronic heart failure [13]. Our patients 
suffered from significant systolic heart failure. Effi-
cacy of the left ventricular (LV) function is further 
compromised in our patients due to severe mitral 
Table 4 Bivariate regressions (MC group; N = 40) of  cognitive performance improvement with  psychological- 
and cognitive malfunctioning, and age before PMVR
TOL Tower of London–Freiburg Version, FGT figural memory test, TMT B trail making test part B, PHQ-9 Patient Health Questionnaire, SF-36 Short-Form Health Survey, 







B 95% CI B 95% CI B 95% CI
TOL − 0.78 [− 1.04, − 0.53] − 0.26 [− 0.69, 0.17] 1.88 [− 0.78, 4.53]
FGT − 0.25 [− 0.39, − 0.10] − 0.26 [− 0.44, − 0.07] 1.08 [− 0.13, 2.29]
TMT B 0.03 [0.01, 0.05] 0.01 [− 0.01, 0.04] − 0.36 [− 0.50, − 0.23]
PHQ‑9a 0.19 [− 0.23, 0.60] 0.12 [− 0.29, 0.52] 1.21 [− 1.83, 4.24]
SF36  mentala − 0.04 [− 0.37, 0.30] − 0.12 [− 0.44, 0.20] 0.06 [− 0.55, 0.67]
SF36  physicala − 0.17 [− 0.54, 0.20] − 0.01 [− 0.36, 0.38] 0.01 [− 0.55, 0.56]
Age 0.10 [− 0.03, 0.23] − 0.05 [− 0.21, 0.11] − 0.29 [− 1.28, 0.71]
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valve regurgitation. Due to mitral valve repair, LV 
volume overload is reduced and, thus, the efficacy of 
LV function can be improved. Systolic LVEF remains 
unaltered, which is expected and in line with previous 
results [29]. Increased cognitive performance appears 
due to the reduction of mitral regurgitation but not 
due to improvement of heart failure. With regard to 
the underlying pathogenesis of HF, our results revealed 
that patients with ICMP vs. DCMP equally improved 
their cognitive as well as mental functioning.
Another important issue is whether the observed 
effects on cognitive function might be a consequence 
of different medical therapy post-MC intervention. 
With regard to this aspect, all patients received sta-
ble optimized individual target heart failure medica-
tion at least for 3 months prior to MC intervention. As 
previously published, no significant alteration in HF 
medication (regarding beta-blockers, ACE inhibitors/
angiotensin receptor blockers and aldosterone recep-
tor inhibitors) was observed within a 12-month post-
MC observation period [29]. Thus, improvement of 
cognitive function is likely to be independent of medi-
cation in our study sample.
In a meta-analysis, McDermott et al. [51] found sig-
nificant correlations between depression severity and 
the cognitive domains executive function, processing 
speed and episodic memory. Likewise, an association 
between depression symptoms, assessed by the Beck 
Depression Inventory II, and impaired executive func-
tioning, measured by the Frontal Assessment Battery, 
has been shown for older patients with HF [52]. Hence, 
the examination of cognitive performance in HF 
patients requires careful consideration of psychologi-
cal well-being, particularly with respect to the assess-
ment of depression symptoms. Most importantly, 
psychosocial functioning (i.e., depression and psycho-
logical/physical well-being) did neither predict base-
line cognitive functioning nor cognitive performance 
outcomes in the MC group, which is in line with previ-
ous results [53], since depressive symptoms in the cur-
rent study are “sub-clinical” and considered as a simple 
somatically caused side effect of HF.
Limitations
A shortcoming of the present study is the small sample 
size which might have limited power to detect signifi-
cant effects. In future studies, additional measurement 
times and longer intervals between assessments might 
be beneficial in the investigation of the MC interven-
tion’s long-term effects on both psychosocial and cog-
nitive parameters.
Conclusions
Our results show that (1) percutaneous mitral valve 
repair using the MitraClip is an efficient tool to 
improve both cognitive and psychological outcomes 
which might be caused by haemodynamic changes in 
HF patients irrespective of the pathogenesis of HF. Sec-
ond (2) HF patients with impaired baseline scores in 
cognitive performance benefited most from the Mitra-
Clip procedure, showing improved executive function 
with post-intervention scores within the normal range. 
Lastly, (3) after careful interdisciplinary discussion, 
the MitraClip procedure should not be withheld from 
elderly HF patients—despite the evidence of reduced 
cognitive reserve.
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